Most of the women filing these cases learned the word meningioma from a radiologist, not from a pill bottle. They had been receiving a contraceptive injection every three months for years, developed headaches, vision changes, or seizures, and an MRI found a tumor on the lining of the brain. The Depo-Provera lawsuit docket exists because of what the label did and did not say about that risk in the United States compared with other countries.
This is a plain description of what the claims allege, where the federal litigation actually stands, and what a person who used the shot should understand before responding to a television ad. Nothing here establishes that the drug caused any particular tumor. That is precisely what the courts have not yet decided.
What the Lawsuits Allege
Depo-Provera is the brand name for an injectable contraceptive containing medroxyprogesterone acetate, a synthetic progestin, given as an intramuscular shot roughly every thirteen weeks. A lower-dose subcutaneous version, depo-subQ provera 104, is also on the market. Pfizer sells the branded product; generic medroxyprogesterone acetate injections are sold by other manufacturers, which matters more than most claimants realize.
The central legal theory is failure to warn. Plaintiffs allege that the manufacturer knew or should have known of a reported association between prolonged use of high-dose medroxyprogesterone acetate and intracranial meningioma, and that product labeling in the United States did not carry a meningioma warning while labeling approved in some other jurisdictions did. The related counts commonly pleaded are design defect, negligence, negligent misrepresentation, and breach of warranty.
Two points are frequently blurred in advertising. First, an allegation in a complaint is not a finding. Second, the meningioma claims are separate from the long-standing bone-density issue: the FDA added a boxed warning about loss of bone mineral density with prolonged use in 2004, and that warning has been on the label for two decades. A claim built on a risk the label already disclosed is a much harder claim.
Where the Litigation Stands
In February 2025 the Judicial Panel on Multidistrict Litigation consolidated the federal cases into MDL No. 3140, captioned In re: Depo-Provera (Depo-Medroxyprogesterone Acetate) Products Liability Litigation, assigned to the United States District Court for the Northern District of Florida before Judge M. Casey Rodgers. Consolidation means pretrial proceedings are centralized before one judge; it does not merge the cases into a single claim, and each plaintiff keeps her own case.
Since consolidation the court has run the usual early machinery of a pharmaceutical MDL: leadership appointments, a plaintiff fact sheet and census process, a master complaint, and coordinated discovery of the manufacturer’s regulatory and safety files. Two contested questions dominate the pretrial phase.
Federal preemption
The manufacturer’s strongest structural defense is that federal drug labeling law preempts state-law failure-to-warn claims. Under the Supreme Court framework from Wyeth v. Levine, a brand manufacturer can generally strengthen a warning unilaterally through the changes-being-effected regulation, but only on the basis of newly acquired information, and preemption applies where there is clear evidence the FDA would have rejected the warning. Expect this issue to be briefed heavily and to shape how many cases survive.
General causation and bellwethers
Before individual trials, MDL courts typically resolve whether the plaintiffs’ expert evidence can support general causation at all, the gatekeeping inquiry under Federal Rule of Evidence 702. A small group of representative cases is then worked up as bellwether trials to give both sides information about jury reactions and settlement value. That sequence takes time; in comparable pharmaceutical MDLs the first bellwether verdicts have often come two to four years after consolidation.
No global settlement, settlement matrix, or court-approved payout schedule exists in this litigation. Any advertisement quoting a per-claimant figure is describing a projection, not an offer.
What the Research Actually Reported
The scientific trigger for the litigation was a study published in The BMJ in 2024 using French national health insurance data, which reported an association between prolonged use of certain progestogens, including injectable medroxyprogesterone acetate, and intracranial meningioma requiring surgery. Meningiomas are usually benign, slow-growing tumors arising from the meninges, the membranes covering the brain and spinal cord, and many are known to carry progesterone receptors, which is the proposed biological mechanism.
Several caveats travel with that finding and both sides will argue them:
- It is an observational study, which can establish association but not causation on its own.
- The reported elevation applied to prolonged use, generally a year or more of exposure, not a single injection.
- Meningiomas occur in the general population without any hormonal exposure, and are more common in women and with increasing age, so background rate is a live issue in every individual case.
- The absolute risk of developing a meningioma remains low even where a relative increase is reported. A large relative number applied to a small baseline is still a small number.
- Bone mineral density loss, the subject of the 2004 boxed warning, is a distinct question and is generally reported to be at least partly reversible after the injections stop.
None of this tells any individual whether her tumor came from the medication. That determination is made case by case, through specific-causation expert testimony and her own medical history.
How an MDL Differs From a Class Action
These are routinely confused, and the difference decides whether a person gets an individual recovery or a share of a common fund.
| Multidistrict litigation (MDL 3140) | Class action | |
|---|---|---|
| Structure | Many individual lawsuits, transferred to one judge for pretrial proceedings | One representative case litigated on behalf of a defined class |
| Do you file your own case? | Yes, each plaintiff files and keeps a separate case | No, class members are typically bound automatically unless they opt out |
| Individual damages | Assessed individually, based on your injury and records | Usually formula-based across the class |
| Trial | Bellwether cases are tried; remaining cases can be remanded to their home courts | A single class trial or a class-wide settlement |
| Typical use | Personal injury from drugs and devices, where injuries vary widely | Economic loss claims that are essentially identical |
| Status here | This is an MDL | No certified personal injury class exists in this litigation |
Who May Have a Claim, and What Records Prove It
Attorneys screening these cases generally look for documented use of the injection, a documented intracranial meningioma diagnosis, and a plausible sequence between the two. The paperwork usually matters more than the narrative, because the manufacturer will contest exposure duration and dating.
- Proof of administration. Clinic or pharmacy records showing each injection date, the product name, and the dose. Records from a college health center, a public health clinic, or a former OB-GYN practice are frequently the weak link and can take weeks to obtain.
- Duration of use. Cases generally focus on sustained use rather than a single dose. Total number of injections and the span of years should be reconstructible from records, not memory.
- Diagnostic imaging. The MRI or CT report identifying the meningioma, plus the radiology images themselves, and any neurosurgical or pathology reports if the tumor was resected.
- Whether the product was branded or generic. This affects who can be sued and how preemption applies, because the legal rules for generic manufacturers differ substantially from those for brand manufacturers.
- Treatment and loss documentation. Surgical records, radiation therapy, follow-up monitoring, out-of-pocket costs, time out of work, and documented residual deficits such as vision loss or seizure disorder.
Deadlines are unforgiving and state-specific. Most states set a personal injury limitations period of two or three years, generally running from when the injury and its probable cause were or should have been discovered, and some states add an outer statute of repose. Anyone diagnosed in the past few years should get the dates evaluated promptly rather than waiting for litigation news, because a missed limitations date ends a case regardless of its merits. Legal experts handling mass torts usually run that calculation before anything else.
Frequently Asked Questions
Should I stop taking the injection?
That is a medical decision, not a legal one, and it belongs with your prescribing clinician. Stopping a contraceptive without an alternative in place carries its own consequences, and return of fertility after this particular injection is often delayed by several months. Bring the meningioma question to your provider and decide together; do not stop or switch based on a lawyer advertisement.
Is there a settlement, and how much is a case worth?
There is no settlement. As of this writing the federal cases remain in pretrial proceedings before the MDL court, with no global resolution, no approved compensation matrix, and no bellwether verdicts to anchor values. Any specific dollar figure circulating in advertising is speculation. Case value, if these claims succeed at all, would ultimately turn on documented injury severity, treatment, and lost earnings.
Can I file if I used a generic medroxyprogesterone injection?
Possibly, but the legal path is harder. Under existing Supreme Court precedent, generic manufacturers must match the brand label and generally cannot be sued for failing to warn differently than the brand. Some claimants in that position pursue theories against the brand manufacturer or other defendants. Bring your pharmacy records so counsel can identify exactly which product you received.
What if my meningioma was found years ago?
Get it evaluated anyway. Many states apply a discovery rule that starts the limitations clock when a claimant knew or reasonably should have known of the link between the injury and the product, which for most people was not before the association was publicly reported. That argument is fact-specific and contested, so the analysis has to be done on your dates, in your state.
Do I have to travel to Florida if I file?
Generally no. Cases are filed in or removed to federal court and transferred to the MDL for coordinated pretrial handling, which is mostly paper and depositions. Depositions are usually taken near the plaintiff. If a case is not resolved in the MDL, it can be remanded to the district where it was originally filed for trial.
What does it cost to consult a lawyer about this?
Product liability claims of this type are almost always handled on contingency, meaning no hourly fee and a percentage of any recovery, with case expenses typically advanced by the firm. Read the fee agreement for the percentage, how expenses are deducted, and whether the percentage rises if the case goes to trial. Firms that publish detailed practice information, such as Benesch Law: A Closer Look at a Top Business Law Firm, History, Growth, Areas of Expertise, give a sense of what a substantive firm profile looks like.
What to Do Next
If you used the injection for a year or more and have been diagnosed with an intracranial meningioma, the single most useful step is to start requesting records now: every injection record from every clinic, and the imaging report that identified the tumor. Records requests routinely take four to eight weeks, they are the gating item for any evaluation, and they are worth having whether or not you ever file. If you used the shot and have no symptoms, there is nothing to file and no reason to panic; raise the question at your next appointment. Related coverage sits in the Business Law section.
This article is general information about pending litigation and is not legal or medical advice; consult a licensed attorney about your claim and your own clinician about your treatment.
